vTv Therapeutics Inc (VTVT) USD0.01 A

Sell:$6.00Buy:$14.81$0.39 (2.54%)

Prices delayed by at least 15 minutes
Sell:$6.00
Buy:$14.81
Change:$0.39 (2.54%)
Prices delayed by at least 15 minutes
Sell:$6.00
Buy:$14.81
Change:$0.39 (2.54%)
Prices delayed by at least 15 minutes

Company Information

About this company

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Key people

Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Steven Tuch
Chief Financial Officer, Executive Vice President
Richard S. Nelson
Executive Vice President - Corporate Development, Director
Srinivas Akkaraju
Independent Director
Fahed Al Marzooqi
Independent Director
Raymond Cheong
Independent Director
Anne M. Phillips
Independent Director
Click to see more

Key facts

  • EPIC
    VTVT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9183852048
  • Market cap
    $46.33m
  • Employees
    16
  • Shares in issue
    2.61m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.